Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
暂无分享,去创建一个
Quan P. Ly | Michael Gibson | Rajesh N Keswani | Prajnan Das | Farhood Farjah | Haeseong Park | Christopher G Willett | Georgia Wiesner | Lawrence R Kleinberg | J. Ajani | C. Willett | J. Hayman | D. Bentrem | P. Enzinger | M. Mulcahy | R. Keswani | Nicole R. McMillian | W. Hofstetter | G. Poultsides | S. Leong | P. Fanta | S. Hochwald | T. D’amico | G. Wiesner | P. Das | L. Kleinberg | H. Gerdes | Q. Ly | C. Denlinger | K. Matkowskyj | F. Farjah | M. Gibson | K. Johung | R. Roses | K. Perry | Haeseong Park | James A Hayman | Jaffer A Ajani | D. Jaroszewski | J. Pimiento | V. Strong | J. Chao | C. Corvera | R. Glasgow | D. Ilson | M. Mcnamara | R. Paluri | C. Wright | L. Pluchino | Mary F Mulcahy | Thomas A D'Amico | David J Bentrem | Joseph Chao | Carlos Corvera | Crystal S Denlinger | Peter C Enzinger | Paul Fanta | Hans Gerdes | Robert E Glasgow | Steven Hochwald | Wayne L Hofstetter | David H Ilson | Dawn Jaroszewski | Kimberly L Johung | Stephen Leong | Quan P Ly | Kristina A Matkowskyj | Michael McNamara | Ravi K Paluri | Kyle A Perry | Jose Pimiento | George A Poultsides | Robert Roses | Vivian E Strong | Cameron D Wright | Nicole R McMillian | Lenora A Pluchino | Nicole R Mcmillian | C. Wright | C. Wright
[1] R. Ginsberg,et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Tournigand,et al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. , 2015, Bulletin du cancer.
[3] L. Leichman,et al. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] J. Hechtman,et al. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. , 2012, Archives of pathology & laboratory medicine.
[5] S. Song,et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Yu-hong Li,et al. Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer , 2010, Chemotherapy.
[7] A. Elsaid,et al. Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer , 2005 .
[8] J. Ajani,et al. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer , 2017, Molecular Cancer Therapeutics.
[9] J. Pignon,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Shah,et al. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. , 2019, Future oncology.
[11] Y. Bang,et al. LBA-009KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] S. Cascinu,et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. , 2018, International journal of surgery.
[13] W. Hohenberger,et al. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial , 2009, Anti-cancer drugs.
[14] B. Vogelstein,et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. , 2016 .
[15] E. Kuipers,et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. , 2017, The Cochrane database of systematic reviews.
[16] N. Sugimoto,et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Stein,et al. Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection , 1996 .
[18] A. Lindgren,et al. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia , 2000, International journal of cancer.
[19] J. Ajani,et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Arsène,et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Thomas,et al. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer , 2010, British Journal of Cancer.
[22] Sung-Bae Kim,et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. , 2019, Journal of Clinical Oncology.
[23] J. Lacy,et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] P. Schirmacher,et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multice , 2016, The Lancet. Oncology.
[25] W. Schmiegel,et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. , 1998, British Journal of Cancer.
[26] S. Nomura,et al. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). , 2016, European journal of cancer.
[27] D. Karnofsky. The clinical evaluation of chemotherapeutic agents in cancer , 1949 .
[28] S. Park,et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy , 2013, Cancer Chemotherapy and Pharmacology.
[29] M. Shah,et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] E. Steyerberg,et al. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Al-Batran,et al. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge? , 2017, Hematology/oncology clinics of North America.
[32] J. Sicklick,et al. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma , 2018, Clinical Cancer Research.
[33] M. Ychou,et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Scott A. Hundahl,et al. Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction , 2001 .
[35] C. Bokemeyer,et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Ajani,et al. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. , 2010, The Annals of thoracic surgery.
[37] D. Shin,et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[38] V. Gebski,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. , 2011, The Lancet. Oncology.
[39] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[40] Yeon-Hee Park,et al. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer , 2008, Cancer Chemotherapy and Pharmacology.
[41] T. Bekaii-Saab,et al. Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[42] W. Allum,et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] G. Beretta,et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.
[44] Sung Sook Lee,et al. Salvage Chemotherapy With Biweekly Irinotecan, Plus 5-Fluorouracil and Leucovorin in Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine, Platinum, and Taxane , 2008, American journal of clinical oncology.
[45] L. Assersohn,et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] C. Willett,et al. Patterns of recurrence after trimodality therapy for esophageal cancer , 2014, Cancer.
[47] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[48] E. Steyerberg,et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. , 2015, The Lancet. Oncology.
[49] J. Isola,et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[50] J. Ajani,et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] J. Lacy,et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[52] J. Ajani,et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis , 2018, OncoTargets and therapy.
[54] Manfred Dietel,et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing , 2010, Virchows Archiv.
[55] H. Ishwaran,et al. Worldwide Esophageal Cancer Collaboration: clinical staging data. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[56] P. Philip,et al. Phase II Study of Paclitaxel and Carboplatin in Patients With Advanced Gastric Cancer , 2003, American journal of clinical oncology.
[57] A. Hinke,et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.
[58] M. Feith,et al. Adenocarcinoma of the Esophago-Gastric Junction , 2006, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.
[59] J. Reynolds,et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. , 2011, Cancer epidemiology.
[60] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[61] C. Reed,et al. Cisplatin/Irinotecan Versus Carboplatin/Paclitaxel as Definitive Chemoradiotherapy for Locoregionally Advanced Esophageal Cancer , 2010, American journal of clinical oncology.
[62] M. J. van de Vijver,et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.
[63] C. Abnet,et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. , 2007, American journal of epidemiology.
[64] S. Parsons,et al. The role of staging laparoscopy in oesophagogastric cancers. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[65] H. Grabsch,et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial , 2017, The Lancet. Oncology.
[66] J. Ajani,et al. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction , 2016, American journal of clinical oncology.
[67] Charles R. Thomas,et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] C. la Vecchia,et al. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] F. Wrba,et al. Expression of Her-2 in Carcinomas of the Esophagus , 2010, The American journal of surgical pathology.
[70] T. Conroy,et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] D. Richel,et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] J. Cooper,et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. , 1999, JAMA.
[73] P. Ganz,et al. Karnofsky performance status revisited: reliability, validity, and guidelines. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] C. Earle,et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] Yoon-Koo Kang,et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[76] E W Steyerberg,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.
[77] A. Jemal,et al. Global Cancer Statistics , 2011 .
[78] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[79] T. Hickish,et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] J. Ajani,et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] K. Moorthy,et al. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma , 2008, The British journal of surgery.
[82] C. Fuchs,et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] J. Zaluski,et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[84] H. Song,et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer , 2010, Cancer Chemotherapy and Pharmacology.
[85] A. Venturi,et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis , 2004, Gut.
[86] D. Brattström,et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. , 2006, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[87] H. Ishwaran,et al. Optimum Lymphadenectomy for Esophageal Cancer Methods Worldwide Esophageal Cancer Collaboration Multivariable Risk-adjusted Survival , 2022 .
[88] S. Kakar,et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] M. Feith,et al. Adenocarcinoma of the Esophagogastric Junction: Results of Surgical Therapy Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients , 2000, Annals of surgery.
[90] A. Amodio,et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort , 2013, Journal of experimental & clinical cancer research : CR.
[91] Kazuhiro Yoshida,et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial , 2018, The Lancet.
[92] D. Richel,et al. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: A phase II study. , 2010 .
[93] D. Sugarbaker,et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] D. Cunningham,et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. , 2014, The Lancet. Oncology.
[95] T. Conroy,et al. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. , 2017, European journal of cancer.
[96] P. Siersema,et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial , 2011, BMC Cancer.
[97] J. Siewert,et al. Are squamous and adenocarcinomas of the esophagus the same disease? , 2007, Seminars in radiation oncology.
[98] G. Wagenius,et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer , 2007, Medical oncology.
[99] J. Ajani,et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] H. Groen,et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] A. Shinagare,et al. Esophageal Carcinoma: Current Concepts in the Role of Imaging in Staging and Management , 2015, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.
[102] J. Ajani,et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] P. Philip,et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial , 2018, JAMA oncology.
[104] Judy L. Smith,et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] T. Hickish,et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF , 2005, British Journal of Cancer.
[106] E. Blackstone,et al. Cancer of the esophagus and esophagogastric junction—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.
[107] R. Heelan,et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. , 2000, Cancer journal.
[108] A. Jimeno,et al. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[109] C. Sima,et al. Esophageal Cancer Recurrence Patterns and Implications for Surveillance , 2013, Journal of Thoracic Oncology.
[110] R. Munden,et al. Esophageal Cancer: The Role of Integrated CT-PET in Initial Staging and Response Assessment After Preoperative Therapy , 2006, Journal of thoracic imaging.
[111] P. V. van Diest,et al. HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma , 2010, Pathology research international.
[112] M. Blaser,et al. Population attributable risks of esophageal and gastric cancers. , 2003, Journal of the National Cancer Institute.
[113] N. Altorki,et al. Predicting Systemic Disease in Patients With Esophageal Cancer After Esophagectomy: A Multinational Study on the Significance of the Number of Involved Lymph Nodes , 2008, Annals of surgery.
[114] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[115] T. Conroy,et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. , 2014, The Lancet. Oncology.
[116] Sung-Bae Kim,et al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study , 2019, JAMA oncology.
[117] M. Ebert,et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[118] J. Lunceford,et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. , 2016, The Lancet. Oncology.
[119] A. Norman,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.
[120] C. Boni,et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[121] A. Benson,et al. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] A. Norman,et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[123] J. Lunceford,et al. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] L. Bardram,et al. Survival after Adjuvant Chemoradiotherapy or Surgery Alone in Resectable Adenocarcinoma at the Gastro-Esophageal Junction , 2012, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.
[125] E. Van Cutsem,et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] J. Urschel,et al. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. , 2002, American journal of surgery.
[127] Ximo Wang,et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials , 2018, PloS one.
[128] S. Yoshida,et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[129] Inkyung Jung,et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. , 2012, European journal of cancer.
[130] F. Lordick,et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[131] T. Demmy,et al. Controversies in the Multimodality Management of Locally Advanced Esophageal Cancer: Evidence-Based Review of Surgery Alone and Combined-Modality Therapy , 2004, Annals of Surgical Oncology.
[132] J. Ajani,et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. , 1994, Journal of the National Cancer Institute.
[133] Y. Bang,et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.
[134] H. Liu,et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. , 2010, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[135] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[136] Naotoshi Sugimoto,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[137] Kathleen M Murphy,et al. [Clinicopathological features and types of microsatellite instability in 1394 patients with colorectal cancer]. , 2020, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
[138] J. Ajani,et al. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[139] D. Ilson. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. , 2004, Oncology.
[140] B. Whitson,et al. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. , 2010, The Journal of thoracic and cardiovascular surgery.
[141] Y. Bang,et al. KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer. , 2017 .
[142] M. Egger,et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial , 2019, The Lancet.
[143] G. Sauter,et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus , 2007, Modern Pathology.
[144] Moon Soo Kim,et al. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.
[145] J. Cooper,et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.